Relatlimab
CA224-020
Phase 2 mab completed
Quick answer
Relatlimab for Neoplasms by Site is a Phase 2 program (mab) at Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb
- Indication
- Neoplasms by Site
- Phase
- Phase 2
- Modality
- mab
- Status
- completed